NASDAQ · RADX
Healthcare · Biotechnology
$2.62
Down-$0.05 (-1.87%)
Updated Aug 19, 2026, 11:03 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
RADX closed at $2.62 after 19 trading sessions, down 38.93% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $2.66 | $2.79 | $2.5501 | $2.62 | 39.47K |
| Aug 17, 2026 | $2.56 | $2.75 | $2.51 | $2.67 | 60.66K |
| Aug 14, 2026 | $2.61 | $2.6888 | $2.45 | $2.56 | 79.34K |
| Aug 13, 2026 | $2.80 | $2.805 | $2.625 | $2.65 | 51.04K |
| Aug 12, 2026 | $2.85 | $2.85 | $2.73 | $2.78 | 28.07K |
| Aug 11, 2026 | $2.78 | $2.86 | $2.75 | $2.86 | 29.48K |
| Aug 10, 2026 | $2.77 | $2.9354 | $2.77 | $2.80 | 10.39K |
| Aug 7, 2026 | $2.90 | $2.9248 | $2.715 | $2.80 | 51.1K |
| Aug 6, 2026 | $2.84 | $2.9929 | $2.62 | $2.79 | 33.95K |
| Aug 5, 2026 | $2.88 | $3.1495 | $2.70 | $2.78 | 76.92K |
| Aug 4, 2026 | $3.04 | $3.06 | $2.86 | $2.92 | 81.79K |
| Aug 3, 2026 | $3.04 | $3.2799 | $2.95 | $3.11 | 83.96K |
| Jul 31, 2026 | $3.00 | $3.24 | $2.95 | $3.15 | 93.68K |
| Jul 30, 2026 | $3.15 | $3.20 | $2.95 | $3.20 | 66.98K |
| Jul 29, 2026 | $3.09 | $3.2845 | $3.00 | $3.15 | 84.34K |
| Jul 28, 2026 | $3.60 | $3.60 | $2.85 | $3.31 | 164.77K |
| Jul 27, 2026 | $3.26 | $3.875 | $3.2001 | $3.66 | 374.56K |
| Jul 24, 2026 | $2.87 | $3.94 | $2.73 | $3.55 | 1.54M |
| Jul 21, 2026 | $4.22 | $4.42 | $4.20 | $4.29 | 35.1K |
The latest Smart Investors Daily articles mentioning RADX.
RADX research
Company profile and research snapshot.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 25, 2026 | JONES TRADING | Buy | — |
| Jan 31, 2026 | JONES TRADING | Buy | — |
| Dec 17, 2025 | JONES TRADING | Buy | — |
| Dec 16, 2025 | JONES TRADING | Buy | — |
| Dec 16, 2025 | BELL POTTER SECURITIES | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 3, 2026
By John Vandermosten, CFA NASDAQ: RADX READ THE FULL RADX RESEARCH REPORT Fiscal 2026 Activity and Cash Flows Radiopharm Theranostics (NASDAQ: RADX) released its Quarterly Activities and Cash Report for its fourth quarter and fiscal year ending June 30 th , 2026. Beyond the review of cash sources and uses for the fiscal year 2026, the report highlighted recent clinical trial achievements for
Yahoo · Jul 31, 2026
Reported positive results from the Phase 2b clinical trial of imaging agent RAD 101, showing 93% of evaluable patients treated with RAD 101 achieved the primary endpoint Plans to initiate Phase 3 registrational trial of RAD 101 in Q4 2026 Raised approximately $12.5M through an institutional offer and launched a $6million Share Purchase Plan, post balance date SYDNEY, July 31, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stag
Benzinga · Jul 24, 2026
Gainers Tenet Healthcare (NYSE:THC) stock increased by 17.3% to $233.54 during Friday's regular session. The market value of their outstanding shares is at $17.4 billion. The company's, Q2 earnings came out
Yahoo · Jul 24, 2026
NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announces that it has entered into a Securities Purchase Agreement (“SPA”) with certain U.S. accredited institutional investors to issue, in a registered direct offering, 1,281,646 American Depositary Share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RADX.
No results
No recent SID articles mention RADX.
